Preclinical WebsiteClinical Website
Table of Contents

Table of Contents

Abstract
01. Landing Page
Presentation
01. Introduction02. Patient Demographics & Features at Baseline03. MRI Deformation Processing04. Thalamus Deformations in PD05. Thalamus Deformations in Controls & Prodromal06. Volumetry vs. Surface Deformations07. Sample Size Power Analysis08. Several ROIs Deformations09. DaTscan SBR in PD10. Midbrain Deformations Predicts DaTscan SBR11. Accuracy of DaTscan SBR Predictions12. Summary
Baseline clinical data

Baseline clinical data for the following measures: Montreal Cognitive Assessment (MoCA), and Unified Parkinson’s Disease Rating Scale (UPDRS) scores are presented as Mean ± SD. Participants in the PD group have significantly higher UPDRS scores and only slightly lower MoCA scores when compared to the Healthy Control and Prodromal participants.

 

DaT SPECT in Healthy Controls

DAT SPEC Healthy Control Scan

DaT SPECT in Parkinson’s Disease at Baseline

DAT SPECT in Parkinson's Disease at Baseline

Data Sources

Data used in the preparation of this presentation were obtained from the Parkinson's Progression Markers Initiative (PPMI). PPMI was launched in 2010 and is conducted in the United States, Europe, Israel, and Australia. The study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research and is made possible by restricted donations to the Foundation from a consortium of Parkinson’s drug development stakeholders. PPMI is led by Principal Investigator Ken Marek, MD, President and Senior Scientist of the Institute for Neurodegenerative Disease in New Haven, Connecticut. The primary goal of PPMI is to identify biological markers of Parkinson’s risk, onset and progression — critical tools for the development of new and better treatments — and to provide the broad research community a comprehensive, standardized, longitudinal data set and biosample library to speed breakthroughs and enable validation toward clinical application of new findings.

--:--

The Parkinson's disease data used for analysis was obtained from the Parkinson's Progression Markers Initiative database. A primary goal of PPMI is to identify biological markers of Parkinson’s disease risk, onset, and progression. N=602 MRI scans from Healthy Control, Prodromal and Sporadic Parkinson’s Disease participants were included in the longitudinal analysis of subcortical deformations, while the prediction analysis of the DaTscan density was performed only on N=326 scans from PD patients with time-concurrent MRI and DaTscan SPECT images.

In both cases, the scans corresponded to an initial baseline visit as well as time visits corresponding to 12, 24 and 48 months after baseline. The cohorts have more male than female participants, particularly within the PD group. Overall, the average age of the participants at baseline visit was around 60 years. Participants in the PD group have significantly higher UPDRS scores and only slightly lower MoCA scores when compared to the Healthy Control and Prodromal participants.

We use necessary cookies to make our site work. We also use other cookies to help us make improvements by measuring how you use the site or for marketing purposes. You have the choice to accept or reject them all. For more detailed information about the cookies we use, see our Privacy Notice.